{"id":521765,"date":"2021-08-03T01:03:04","date_gmt":"2021-08-03T05:03:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/obseva-to-present-at-upcoming-investor-conferences\/"},"modified":"2021-08-03T01:03:04","modified_gmt":"2021-08-03T05:03:04","slug":"obseva-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/obseva-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"ObsEva to Present at Upcoming Investor Conferences"},"content":{"rendered":"
\n

\n GENEVA, Switzerland<\/strong>
\n August 3<\/strong>
\n , 202<\/strong>
\n 1<\/strong>
\n \u2013 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), <\/strong>a biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s reproductive health, today announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st<\/sup> Annual Growth Conference to be held August 10-12, 2021.<\/p>\n

Details on the presentations can be found below.<\/p>\n

\u00a0<\/p>\n

\n Wedbush <\/strong>
\n PacGrow<\/strong>
\n Healthcare Conference<\/strong>\n <\/p>\n

Date: Wednesday, August 11, 2021
Presentation Time: 8 a.m. EST
Webcast: Click Here<\/a><\/p>\n

\u00a0<\/p>\n

\n Canaccord Genuity 41<\/strong>
\n
\n st<\/strong>
\n <\/sup>
\n Annual Growth Conference<\/strong>\n <\/p>\n

Date: Thursday, August 12, 2021
Presentation Time: 9 a.m. EST
Webcast: Click Here<\/a><\/p>\n

The presentations and archived webcasts will also be accessible under “Events Calendar” in the investors section of ObsEva’s website<\/a>.<\/p>\n

\u00a0<\/p>\n

\n About ObsEva<\/strong>\n <\/p>\n

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol \u201cOBSV\u201d and on the SIX Swiss Exchange where it is trading under the ticker symbol \u201cOBSN\u201d. For more information, please visit\u00a0www.ObsEva.com<\/a>.<\/p>\n

\u00a0<\/p>\n

\n For further information, please contact: <\/strong>\n <\/p>\n

\n CEO Office contact<\/strong>
\n
Shauna Dillon
Shauna.dillon@obseva.ch<\/a>
+41 22 552 1550<\/p>\n

\n Investor Contact<\/strong>
\n
Joyce Allaire
jallaire@lifesciadvisors.com<\/a>
+1 (617)-435-6602<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n